Literature DB >> 11314782

p53 protein expression and gene mutation in phyllodes tumors of the breast.

Z Gatalica1, S Finkelstein, E Lucio, O Tawfik, J Palazzo, B Hightower, E Eyzaguirre.   

Abstract

The malignant potential of mammary phyllodes tumors is difficult to assess on initial pathologic examination. Studies on the p53 tumor suppressor gene have shown that it has an important role in the development of a variety of malignancies, yet the specific contribution to the pathogenesis and development of the malignant potential of phyllodes tumor is largely unknown. We studied p53 protein expression in 25 cases of phyllodes tumors histologically classified as either malignant (12 cases) or benign (13 cases). Using microdissection approach, we also analyzed the p53 gene sequence in a case that demonstrated progression from benign to malignant phenotype. Nuclear p53 staining was detected in various proportions (1-90%) of neoplastic stromal cells of malignant tumors. No staining was found in benign tumors. Progression from benign to malignant phenotype was associated with a significant increase in the accumulation of p53 (more than 20 times). This was caused by an underlying missense mutation in exon 7, resulting in a change from Arg248 to Trp248 in the malignant component of the tumor. Stromal p53 over-expression was observed only in neoplasms histologically classified as malignant and was associated with an increased proliferation index (MIB-1 staining). These two markers may be used as useful adjuncts in the diagnosis of malignancy in difficult cases or when only a limited sample size is available. Somatic mutation in exon 7 of p53 gene in malignant phyllodes tumor points toward the importance of p53 in the malignant transformation of phyllodes tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314782     DOI: 10.1078/0344-0338-00031

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

Review 1.  Optimising preoperative diagnosis in phyllodes tumour of the breast.

Authors:  R K Jacklin; P F Ridgway; P Ziprin; V Healy; D Hadjiminas; A Darzi
Journal:  J Clin Pathol       Date:  2006-02-06       Impact factor: 3.411

2.  Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.

Authors:  Su-Yang Liu; Nancy M Joseph; Ajay Ravindranathan; Bradley A Stohr; Nancy Y Greenland; Poonam Vohra; Elizabeth Hosfield; Iwei Yeh; Eric Talevich; Courtney Onodera; Jessica A Van Ziffle; James P Grenert; Boris C Bastian; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

3.  Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.

Authors:  Zoran Gatalica; Semir Vranic; Anatole Ghazalpour; Joanne Xiu; Idris Tolgay Ocal; John McGill; Ryan P Bender; Erin Discianno; Aaron Schlum; Souzan Sanati; Juan Palazzo; Sandeep Reddy; Barbara Pockaj
Journal:  Oncotarget       Date:  2016-01-12

4.  Primary Breast Tumors with Mesenchymal Morphology.

Authors:  Manvir S Tevatia; Prabhashankar Mishra; Ajay K Baranwal; Prachi B Nichat; Divya Shelly; Shivali Awasthi; Prashant Sengupta
Journal:  J Lab Physicians       Date:  2021-07-09

5.  Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.

Authors:  Denis L Fontes Jardim; Anthony Conley; Vivek Subbiah
Journal:  Orphanet J Rare Dis       Date:  2013-07-30       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.